Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

233 trials with published results (14%)

Research Maturity

1077 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

109 terminated out of 1717 trials

Success Rate

90.8%

+4.3% vs benchmark

Late-Stage Pipeline

17%

300 trials in Phase 3/4

Results Transparency

22%

233 of 1077 completed with results

Key Signals

233 with results91% success109 terminated

Data Visualizations

Phase Distribution

1,255Total
Not Applicable (681)
Early P 1 (15)
P 1 (99)
P 2 (160)
P 3 (166)
P 4 (134)

Trial Status

Completed1,077
Unknown296
Terminated109
Recruiting101
Withdrawn58
Active Not Recruiting38

Trial Success Rate

90.8%

Benchmark: 86.5%

Based on 1077 completed trials

Clinical Trials (1717)

Showing 20 of 20 trials
NCT07073950Phase 4RecruitingPrimary

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation

NCT05984823Not ApplicableCompletedPrimary

Home-based Body Weight Exercise With Blood Flow Restriction (BFR): Feasibility of a Novel Rehabilitation Intervention in COPD Patients (HomeBFR-COPD)

NCT07512687Not ApplicableRecruiting

Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia

NCT07016412Phase 2Active Not RecruitingPrimary

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

NCT06390345Not ApplicableRecruitingPrimary

Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention

NCT06862206RecruitingPrimary

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

NCT07566195Phase 3RecruitingPrimary

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

NCT06981078Phase 2Active Not RecruitingPrimary

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT03647462Not ApplicableWithdrawn

Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients

NCT06334575Phase 4RecruitingPrimary

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

NCT06601777Not ApplicableActive Not RecruitingPrimary

Evaluation of the Effectiveness, Safety, and Cost of a Smart Hospital System for Patients With Chronic Obstructive Pulmonary Disease

NCT05061368Phase 2RecruitingPrimary

Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

NCT04231760Phase 1Not Yet RecruitingPrimary

The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD

NCT06603246Phase 1Recruiting

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT07474220RecruitingPrimary

Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease

NCT05878769Phase 3RecruitingPrimary

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT06944925Phase 1RecruitingPrimary

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

NCT05572333Phase 2CompletedPrimary

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

NCT07069829RecruitingPrimary

Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

NCT04536675Phase 3Active Not RecruitingPrimary

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Scroll to load more

Research Network

Activity Timeline